Concentrations of polychlorinated biphenyls (PCBs) in blood and breast milk collected from 125 mothers in Hokkaido, Japan

Kajiwara J¹, Todaka T², Hori T¹, Yoshitomi H¹, Hirakawa H¹, Yasutake D¹, Onozuka D¹, Miyashita C³, Sasaki S³, Yoshioka E³, Yuasa M³, Kishi R³, Iida T⁴, Yoshimura T¹, and Furue M²

¹Fukuoka Institute of Health and Environmental Sciences, Mukaizano 39, Dazaifu-city, Fukuoka 818-0135, Japan; ²Department of Dermatology, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka-city 812-8582, Japan; ³Department of Public Health, Hokkaido University Graduate School of Medicine, Kita 15, Nishi 5, Kita-ku, Sapporo-city, 060-8638, Japan

⁴Kitakyushu Life Science Center, 1-4 Nakabarushinmati, Tobata-ku, Kitakyushu-city, 804-0003, Japan

Abstract

In this study, we determined the concentrations of PCBs in the blood of pregnant women and in breast milk from the same mothers collected between 2002 and 2005 from 125 mothers living in Hokkaido, Japan. We also investigated the relationship between concentrations of PCBs in the blood and the breast milk. The ratio of PCB congeners in the blood and in breast milk were found to be quite similar, and significant positive correlations between total PCBs concentrations in the blood and breast milk were observed. These results suggest that PCBs accumulated in the blood can be transferred to the breast milk. However, the breast milk-to-blood concentration ratios of each congener of PCBs tended to decrease with higher chlorinated congeners.

Introduction

Polychlorinated biphenyls (PCBs) are widespread environmental contaminants; they accumulate in the human body through the food chain¹ and are present in the blood and in breast milk. The effects of presistent organic pollutants (POPs), including PCBs, have been of great concern in the field of public health, and there is strong interest in determining the influence of these chemicals on the health of fetuses and infants. We have previously reported² the concentrations of dioxin and related chemicals, including dibenzo-*p*-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs), non-*ortho* coplanar polychlorinated biphenyls (non-*ortho* PCBs), and mono-*ortho* coplanar polychlorinated biphenyls (mono-*ortho* PCBs) in the blood of pregnant women and in breast milk.

In this study, we determined the concentrations of PCBs in the blood of pregnant women and in breast milk from the same mothers; samples were collected between 2002 and 2005 from 125 mothers living in Hokkaido, Japan. We also investigated the relationship between concentrations of PCBs in the blood and in breast milk.

Materials and Methods

The blood and breast milk samples were collected between 2002 and 2005 from 125 mothers who had given their informed consent. The blood samples were collected from the maternal peripheral vein after the second trimester during their last pregnancy. The maternal milk specimens were collected 1 month after delivery. The mothers' ages ranged from 21 to 47 (mean: 31.3). After collection, the blood and breast milk samples were stored at -30°C until analyses for concentrations of PCBs.

The extraction of PCBs from the samples was performed using a previously reported method^{3,4}. The PCB concentrations were measured using high-resolution gas chromatography/high-resolution mass spectrometry ⁵. To estimate the total concentrations of PCBs, we introduced ND (less than the detection limit) values to half values of the detection limit.

Results and discussion

Of the 209 PCB congeners, 66 were identified in the blood and breast milk in the present study (Table 1). The arithmetic mean total PCB concentrations in the blood and breast milk were 132.4 (median: 120.9) and 102.5 (median: 88.6) ng /g lipid, respectively, and the concentrations were in the range of 38.1-358.8 and 31.0-404.7 ng /g lipid, respectively (Table 1). The sum of the ratios of the concentrations of pentaCBs, hexaCBs, and heptaCBs to the total concentrations of PCB congeners in the blood and breast milk were 86.5 and 89.5%, respectively. The hexaCBs ratios in the blood and breast milk were 42.8 and 50.4%, respectively, which were the


Table 1. Concentrations of PCBs in the blood of pregnant women and breast milk


| | Concentration (pg / g lipid) Blood (n=125) Breast Milk (n=125) | | | | | | | | | | Ratio |
|--|---|--------------|---------------------|---------------|-----------------|----------------|--------------|---------------------|---------------|-----------------|-----------------|
| Congeners | Mean | Ratio(%) | SD | Min | Max | Mean | Ratio(%) | SD | Min | Max | (Milk/Blood) |
| 245-TrCB(#29) | 14 | 0.0 | 22.20 | 5 | 144 | 6 | 0.0 | 3.54 | 5 | 26 | 44.5% |
| 244'-TrCB(#28) | 1186 | 0.9 | 641.35 | 42 | 4665 | 811 | 0.8 | 461.21 | 145 | 2997 | 68.4% |
| 344'-TrCB(#37) | 618 | 0.5 | 1741.70 | 5 | 16060 | 9 | 0.0 | 17.82 | 5 | 154 | 1.4% |
| 22'55'-TeCB(#52) | 764 | 0.6 | 519.18 | 5 | 3147 | 349 | 0.3 | 321.15 | 5 | 2075 | 45.7% |
| 22'45'-TeCB(#49) | 223 | 0.2 | 147.39 | 5 | 850 | 71 | 0.1 | 50.83 | 5 | 261 | 31.6% |
| 22'44'-TeCB(#47) 22'35'-TeCB(#44) | 435 318 | 0.3 | 260.80 214.97 | 5 5 | 1512 1195 | 207 86 | 0.2 | 113.61 56.19 | 5 5 | 612 306 | 47.5% 27.0% |
| 23'4'6-TeCB(#44) | 101 | 0.2 | 107.26 | 5 | 708 | 42 | 0.0 | 36.77 | 5 | 196 | 41.6% |
| 234'5-TeCB(#63) | 57 | 0.0 | 35.37 | 5 | 194 | 58 | 0.1 | 31.40 | 5 | 232 | 101.3% |
| 244'5-TeCB(#74) | 3666 | 2.8 | 1945.13 | 784 | 13440 | 4038 | 3.9 | 2417.85 | 851 | 20023 | 110.1% |
| 23'4'5-TeCB(#70) | 169 | 0.1 | 103.73 | 5 | 522 | 58 | 0.1 | 43.03 | 5 | 300 | 34.2% |
| 23'44'-TeCB(#66) | 799 | 0.6 | 434.18 | 218 | 2075 | 803 | 0.8 | 450.51 | 173 | 3153 | 100.6% |
| 233'4'-/2344'TeCBs(#56/60) | 305 | 0.2 | 166.80 | 51 | 923 | 325 | 0.3 | 179.42 | 57 | 1115 | 106.5% |
| 22'35'6-PeCB(#95) 22'355'-PeCB(#92) | 463 358 | 0.3 | 225.83 208.16 | 18 21 | 1140 1082 | 262 318 | 0.3 | 158.29 202.93 | 27 5 | 798 1186 | 56.7% 88.7% |
| 22'455'-PeCB(#101) | 830 | 0.5 | 434.34 | 146 | 2242 | 743 | 0.3 | 429.03 | 5 | 2516 | 89.5% |
| 22'44'5-PeCB(#99) | 4637 | 3.5 | 2220.40 | 1044 | 11767 | 4851 | 4.7 | 2559.06 | 947 | 16596 | 104.6% |
| 234'56-PeCB(#117) | 344 | 0.3 | 207.61 | 54 | 1453 | 255 | 0.2 | 157.65 | 5 | 1097 | 74.1% |
| 22'345'-PeCB(#87) | 341 | 0.3 | 220.88 | 62 | 2071 | 207 | 0.2 | 113.39 | 5 | 795 | 60.6% |
| 22'344'-PeCB(#85) | 129 | 0.1 | 112.60 | 5 | 1083 | 90 | 0.1 | 57.97 | 5 | 317 | 69.9% |
| 233'4'6-PeCB(#110) | 243 | 0.2 | 188.11 | 5 | 1524 | 140 | 0.1 | 105.43 | 5 | 771 | 57.5% |
| 233'4'5-PeCB(#107) | 395 | 0.3 | 263.98 | 58 | 1676 | 352 | 0.3 | 230.86 | 5 | 1670 | 89.2% |
| 2'344'5-PeCB(#123) 23'44'5-PeCB(#118) | 132 6707 | 0.1 5.1 | 77.21 3438.68 | 19 1381 | 497 19088 | 113 7006 | 0.1 6.8 | 71.72 3935.53 | 5 1440 | 531 29091 | 85.5% 104.5% |
| 2344'5-PeCB(#114) | 417 | 0.3 | 235.89 | 81 | 1519 | 400 | 0.4 | 225.91 | 94 | 1708 | 96.0% |
| 233'44'-PeCB(#105) | 1630 | 1.2 | 852.88 | 372 | 4879 | 1712 | 1.7 | 953.02 | 303 | 6952 | 105.1% |
| 22'355'6-HxCB(#151) | 489 | 0.4 | 361.28 | 75 | 2605 | 415 | 0.4 | 294.92 | 54 | 2337 | 84.8% |
| 22'33'56'-HxCB(#135) | 188 | 0.1 | 114.88 | 5 | 578 | 166 | 0.2 | 101.44 | 5 | 544 | 88.7% |
| 22'34'56-HxCB(#147) | 147 | 0.1 | 93.30 | 5 | 583 | 147 | 0.1 | 99.13 | 5 | 834 | 100.2% |
| 22'344'6-/22'34'5'6-HxCB(#139/149) | 273 | 0.2 | 187.39 | 5 | 881 | 282 | 0.3 | 159.60 | 5 | 897 | 103.4% |
| 22'33'56-HxCB(#134) | 13 | 0.0 | 13.54 | 5 5 | 86 | 9 5 | 0.0 | 9.42 | 5 5 | 63 | 67.0% |
| 233'55'6-HxCB(#165) 22'34'55'-HxCB(#146) | 5 3746 | 0.0 2.8 | 0.00 2116.33 | 802 | 5 13645 | 3490 | 0.0 3.4 | 0.00 2105.16 | 754 | 5 14622 | 100.0% 93.2% |
| 22'33'46'-HxCB(#132) | 111 | 0.1 | 94.22 | 5 | 452 | 82 | 0.1 | 79.20 | 5 | 340 | 74.4% |
| 22'44'55'-HxCB(#153) | 26235 | 19.8 | 13205.62 | 5721 | 77686 | 24313 | 23.7 | 14240.55 | 6917 | 100807 | 92.7% |
| 22'3455'-HxCB(#141) | 132 | 0.1 | 105.08 | 5 | 537 | 113 | 0.1 | 75.61 | 5 | 406 | 85.4% |
| 22'344'5-HxCB(#137) | 896 | 0.7 | 416.67 | 217 | 2297 | 815 | 0.8 | 451.17 | 223 | 3194 | 91.0% |
| 22'33'45'-HxCB(#130) | 821 | 0.6 | 429.13 | 190 | 2806 | 793 | 0.8 | 511.52 | 5 | 3674 | 96.5% |
| 233'4'5'6-HxCB(#164) | 5141 | 3.9 | 2985.38 | 1187 | 18475 | 4019 | 3.9 | 2364.08 | 1045 | 16592 | 78.2% |
| 22'344'5'-HxCB(#138) | 14377 462 | 10.9 | 7161.63 470.10 | 3214 82 | 44627 4766 | 13450 345 | 13.1 | 7574.65 220.40 | 3954 48 | 52606 | 93.6% |
| 22'33'44'-HxCB(#128) 23'44'55'-HxCB(#167) | 861 | 0.3 | 443.94 | 166 | 2420 | 706 | 0.3 | 426.75 | 169 | 1287 3184 | 74.7% 81.9% |
| 233'44'5-HxCB(#156) | 2197 | 1.7 | 1100.94 | 376 | 6026 | 2003 | 2.0 | 1145.41 | 419 | 7839 | 91.1% |
| 233'44'5'-HxCB(#157) | 516 | 0.4 | 254.01 | | 1562 | 463 | 0.5 | 256.71 | 102 | 1858 | 89.7% |
| 22'33'566'-HpCB(#179) | 88 | 0.1 | 77.89 | 72 5 | 658 | 86 | 0.1 | 63.12 | 5 | 368 | 96.8% |
| 22'33'55'6-HpCB(#178) | 1845 | 1.4 | 1206.10 | 382 | 7130 | 1277 | 1.2 | 830.27 | 305 | 5858 | 69.2% |
| 22'344'56-HpCB(#182) | 8292 | 6.3 | 5702.62 | 2065 | 36848 | 5154 | 5.0 | 3608.36 | 1357 | 30335 | 62.2% |
| 22'344'5'6-HpCB(#183) | 2185 | 1.7 | 1480.38 | 662 | 11206 | 1398 | 1.4 | 924.38 | 424 | 8141 | 64.0% |
| 22'344'56-HpCB(#181) 22'33'4'56-HpCB(#177) | 31 1926 | 0.0 1.5 | 25.49 1287.43 | 5 402 | 129 7121 | 16 1388 | 0.0 1.4 | 13.38 945.09 | 5 232 | 62 7877 | 53.2% 72.0% |
| 22'33'455'-HpCB(#177) | 999 | 0.8 | 666.26 | 254 | 3877 | 533 | 0.5 | 349.53 | 141 | 2570 | 53.3% |
| 22'344'55'-HpCB(#180) | 18832 | 14.2 | 12395.37 | 4323 | 75056 | 9801 | 9.6 | 6128.09 | 2812 | 44516 | 52.0% |
| 233'44'5'6-HpCB(#191) | 217 | 0.2 | 143.81 | 5 | 744 | 110 | 0.1 | 67.12 | 5 | 438 | 50.5% |
| 22'33'44'5-HpCB(#170) | 6463 | 4.9 | 4142.24 | 1503 | 24488 | 3620 | 3.5 | 2241.18 | 994 | 15721 | 56.0% |
| 233'44'55'-HpCB(#189) | 278 | 0.2 | 150.61 | 29 | 808 | 181 | 0.2 | 103.18 | 47 | 671 | 65.0% |
| 22'33'55'66'-OcCB(#202) | 586 | 0.4 | 352.84 | 117 | 2087 | 340 | 0.3 | 247.27 | 89 | 1798 | 58.0% |
| 22'33'45'66'-OcCB(#200) 22'23'45** OcCB(#201/108) | 115 | 0.1 1.8 | 68.89 | 5 483 | 393 | 60 1075 | 0.1 1.0 | 45.92 | 5 267 | 377 5186 | 52.0% |
| 22'33'45**-OcCB(#201/198) 22'344'55'6-OcCB(#203) | 2428 2033 | 1.5 | 1453.89 1169.56 | 483 356 | 10610 7503 | 900 | 0.9 | 772.24 587.32 | 5 | 4045 | 44.3% 44.3% |
| 22'33'44'56-OcCB(#195) | 484 | 0.4 | 270.37 | 83 | 1556 | 272 | 0.3 | 165.43 | 76 | 1227 | 56.2% |
| 22'33'44'55'-OcCB(#194) | 2070 | 1.6 | 1154.80 | 526 | 7090 | 904 | 0.9 | 610.47 | 240 | 4123 | 43.7% |
| 233'44'55'6-OcCB(#205) | 94 | 0.1 | 47.61 | 5 | 300 | 37 | 0.0 | 28.43 | 5 | 195 | 39.8% |
| 22'33'455'66'-NoCB(#208) | 244 | 0.2 | 166.43 | 52 | 1045 | 82 | 0.1 | 68.17 | 5 | 465 | 33.7% |
| 22'33'44'566'-NoCB(#207) | 123 | 0.1 | 74.72 | 5 | 438 | 40 | 0.0 | 28.39 | 5 | 196 | 32.3% |
| 22'33'44'55'6-NoCB(#206) | 641 522 | 0.5 | 370.14 | 100 | 2278 | 190 | 0.2 | 132.84 | <u>5</u> 5 | 857 | 29.7% |
| 22'33'44'55'66'-DeCB(#209) | 532 | 0.4 | 342.20 | 181 | 3300 | 77 | 0.1 | 55.66 | | 377 | 14.4% |
| Total TriCBs | 1818 | 1.4 | 1861.03 | 361 | 17655 | 826 | 0.8 | 460.47 | 155 | 3007 | 45.5% |
| Total PentaCBs | 6839 | 5.2 | 2739.53 | 2394 | 19554 | 6037 | 5.9 | 3201.66 | 1683 | 27132 | 88.3% |
| Total PentaCBs Total HexaCBs | 16626 56609 | 12.6 42.8 | 7680.27 27983.84 | 5946 13367 | 45252 174399 | 16449 51615 | 16.1 50.4 | 8666.35 29435.81 | 3695 15650 | 63891 207088 | 98.9% 91.2% |
| Total HexaCBs Total HeptaCBs | 41156 | 31.1 | 26810.04 | 10109 | 167563 | 23562 | 23.0 | 15028.94 | 6906 | 116464 | 57.2% |
| Total OctaCBs | 7809 | 5.9 | 4408.88 | 1932 | 29270 | 3589 | 3.5 | 2419.51 | 968 | 16951 | 46.0% |
| Total NonaCBs | 1008 | 0.8 | 589.94 | 204 | 3506 | 312 | 0.3 | 221.35 | 15 | 1519 | 31.0% |
| Total DecaCBs | 532 | 0.4 | 342.20 | 181 | 3300 | 77 | 0.1 | 55.66 | 5 | 377 | 14.4% |
| | 122206 | 100.0 | 65868.58 | 38133 | 358816 | 102466 | 100.0 | 57425.57 | 31036 | 403721 | 77.4% |
| Total PCBs | 132396 | 100.0 | 03000.30 | 30133 | 330010 | 102400 | 100.0 | 31723.31 | 31030 | 103721 | 7 7 1 1 7 0 |

CB:chlorinated biphenyl, SD:standard deviation

highest values compared with those of the other congeners. HexaCB-153 among hexaCBs congeners, the most abundant congener in the blood and breast milk, contributed 19.8 and 23.7% to the total concentrations of PCB congeners, respectively. Among the PCB congeners measured in the present study, pentaCB-118, hexaCB-138, heptaCB-180, hexaCB153, heptaCB-182 also showed high ratios to total concentrations of these PCBs congeners in the blood breast milk. The concentrations of these congeners in the blood and breast milk contributed approximately 56.2 58.3% of and the concentrations of PCB congeners, respectively. Other PCB congeners contributed less than 5% of total concentrations of PCB congeners. The PCB congeners ratios in the blood and breast milk were quite similar. In addition, significant positive correlations between total PCBs concentrations in the blood and breast milk were observed (Fig. 1). These results suggest that PCBs accumulated in the blood can be transferred to breast milk.

The breast milk mean total PCBs concentration was approximately 23% lower than that of the blood. The mean total concentrations of tetraCBs, hexaCBs, heptaCBs, and octaCBs in the blood were 6.8, 16.5, 56.6, 41.2, and 7.8 ng/g lipid, and in the breast milk were 6.0, 16.4, 51.6, 23.6, and 3.6 ng /g lipid,





respectively (Fig. 2). The total concentrations of heptaCBs and octaCBs in the breast milk were 43 and 54 % lower than those in the blood, while the total concentrations of pentaCBs and hexaCBs in the breast milk were similar to those in the blood. The breast milk-to-blood concentration ratios of each PCB congener tended to decrease with higher chlorinated congeners.

In a previous study², we measured the concentrations of PCDDs, PCDFs, and dioxin-like PCBs in the blood and breast milk of 125 pregnant women in Hokkaido. The results indicated that the breast milk-to-blood concentration ratios of each congener of PCDDs, PCDFs, non-*ortho* PCBs, and mono-*ortho* PCBs tended to decrease with higher chlorinated congeners.

In this study, we measured the concentrations of PCBs in the blood of pregnant women and in breast milk of the same mothers. These results will be used as basic data for study of the influence of PCBs on the health of fetuses and infants.

Acknowledgment

This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Health, Labour, and Welfare, Japan.

References

- 1. Chen HL, Lee CC, Liao PC, Guo YL, Chen CH, Su HJ. Environ. Res. 2003; 91: 172
- 2. Kajiwara J, Todaka T, Hirakawa H, Hori T, Yasutake D, Onozuka D, Washino N, Konishi K, Sasaki S, Yoshioka E, Yuasa M, Kishi R, Iida T, Yoshimura T, Furue M. *Organohalogen Compound* 2008; 70: 1594
- 3. Todaka T, Hirakawa H, Tobiishi K, Iida T. Fukuoka Igaku Zasshi 2003; 94: 148
- 4. Hori T, Tobiishi K, Ashizuka Y, Nakagawa R, Todaka T, Hirakawa H, Iida T. *Fukuoka Igaku Zasshi* 2005; 96(5): 220
- 5. Iida T, Hirakawa H, Matsueda T, Takenaka S, Nagayama J. Chemosphere 1999; 38(15): 3497